GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neurotech International Ltd (ASX:NTI) » Definitions » ROE % Adjusted to Book Value

Neurotech International (ASX:NTI) ROE % Adjusted to Book Value : -18.41% (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Neurotech International ROE % Adjusted to Book Value?

Neurotech International's ROE % for the quarter that ended in Dec. 2024 was -168.85%. Neurotech International's PB Ratio for the quarter that ended in Dec. 2024 was 9.17. Neurotech International's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -18.41%.


Neurotech International ROE % Adjusted to Book Value Historical Data

The historical data trend for Neurotech International's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurotech International ROE % Adjusted to Book Value Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -52.35 -3.63 -36.13 -10.96

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.55 -17.00 -2.41 -17.84 -18.41

Competitive Comparison of Neurotech International's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Neurotech International's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurotech International's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neurotech International's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Neurotech International's ROE % Adjusted to Book Value falls into.


;
;

Neurotech International ROE % Adjusted to Book Value Calculation

Neurotech International's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-63.92% / 5.83
=-10.96%

Neurotech International's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-168.85% / 9.17
=-18.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurotech International ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Neurotech International's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurotech International Business Description

Traded in Other Exchanges
N/A
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Neurotech International Ltd is a medical device and solutions company conducting clinical studies to assess the neuroprotective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. Geographically, all the firm's business activities function through the region of Australia. It operates in one segment: Medical Device Development and Distribution.

Neurotech International Headlines

From GuruFocus

How to Capitalize on the Bakken Oil Boom

By Vitaliy Katsenelson Vitaliy Katsenelson 11-09-2013

9 Stocks With Yields Over 10% And Buy Or Better Rating

By Dividend Dividend 08-17-2013

20 Stocks with Yields over 10% and Highest Buy Ratings

By Dividend Dividend 01-17-2013

13 Stocks With Dividend Yields Over 10%

By Dividend Dividend 11-12-2014